Compare Adaptive Biotechnologies Corp (ADPT) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs YieldMax AMD Option Income Strategy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $19.89 (market cap $3.33B), while YieldMax AMD Option Income Strategy ETF trades at $52.65. Which is the better fit depends on your goals.
| ADPT | AMDY | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $22.37 | $59.52 |
52-Week Low | $10.24 | $29.80 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
AMDY trades at $56.10, up 5.35% in the last 24 hours, with technical indicators showing a bullish trend. The stock exhibits strong weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights high-yield potential alongside concerns over net asset value erosion due to its option income strategy.
The outlook for AMDY is mixed; high dividend yields attract income investors, but structural risks from NAV erosion and dependency on AMD's stock performance pose significant challenges. Investors should weigh the income benefits against potential capital depreciation in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →
